Prosecution Insights
Last updated: April 19, 2026

Beren Therapeutics P B C

4 pending office actions

Portfolio Summary

4
Total Pending OAs
2
Final Rejections
2
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18365835 METHODS FOR THE TREATMENT OF FAMILIAL HETEROZYGOUS AND HOMOZYGOUS HYPERCHOLESTEROLEMIA WITH CYCLODEXTRINS GALSTER, SAMUEL LEONARD 1693 Non-Final OA Aug 04, 2023
18023325 METHODS FOR THE TREATMENT OF CARDIOVASCULAR DISEASE WITH CYCLODEXTRINS MILLER, DALE R 1693 Final Rejection Feb 24, 2023
18043009 METHODS FOR THE PREVENTION OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS MILLER, DALE R 1693 Final Rejection Feb 24, 2023
18043013 METHODS FOR THE TREATMENT OF CHOLESTEROL CRYSTAL EMBOLIZATION WITH CYCLODEXTRINS MILLER, DALE R 1693 Non-Final OA Feb 24, 2023

Managing Beren Therapeutics P B C's Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month